BR0212093A - Quimeras de proteìna de envelope viral/receptor e métods de utilização - Google Patents

Quimeras de proteìna de envelope viral/receptor e métods de utilização

Info

Publication number
BR0212093A
BR0212093A BR0212093-3A BR0212093A BR0212093A BR 0212093 A BR0212093 A BR 0212093A BR 0212093 A BR0212093 A BR 0212093A BR 0212093 A BR0212093 A BR 0212093A
Authority
BR
Brazil
Prior art keywords
receptor
methods
virus
chimeric
envelope protein
Prior art date
Application number
BR0212093-3A
Other languages
English (en)
Inventor
Devico
Anthony
Fouts
Timothy
Tuskan
G Robert
Original Assignee
Univ Maryland Marylandd Biotec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Marylandd Biotec filed Critical Univ Maryland Marylandd Biotec
Publication of BR0212093A publication Critical patent/BR0212093A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

"QUIMERAS DE PROTEìNA DE ENVELOPE VIRAL/RECEPTOR E MéTODOS DE UTILIZAçãO". A invenção refere-se a moléculas quiméricas compreendendo uma seq³ência de capa viral e uma seq³ência de receptor que podem interagir entre si para formar um complexo que é capaz de ligar um co-receptor. Tais moléculas quiméricas, por esta razão, exibem características e propriedades funcionais de um complexo receptor-proteína de capa, e são úteis como agentes que inibem infecção viral de células, devido à ocupação de um co-receptor presente na célula. Em aspectos particulares, o polipeptídeo quimérico inclui um polipeptídeo de envelope de vírus de imunodeficiência, tal como HN, SN, FIV, FeL V, FPV e herpesvírus. As sequencias de receptor adequadas para utilização em um polipeptídeo quimérico incluem, por exemplo, seq³ências CD4 D1D2 e CD4M9.
BR0212093-3A 2001-08-21 2002-08-21 Quimeras de proteìna de envelope viral/receptor e métods de utilização BR0212093A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/934,060 US6908612B2 (en) 1999-10-08 2001-08-21 Virus coat protein/receptor chimeras and methods of use
PCT/US2002/026543 WO2003016333A2 (en) 2001-08-21 2002-08-21 Virus coat protein/receptor chimeras and methods of use

Publications (1)

Publication Number Publication Date
BR0212093A true BR0212093A (pt) 2004-11-30

Family

ID=25464900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212093-3A BR0212093A (pt) 2001-08-21 2002-08-21 Quimeras de proteìna de envelope viral/receptor e métods de utilização

Country Status (13)

Country Link
US (2) US6908612B2 (pt)
EP (1) EP1425036A4 (pt)
JP (1) JP4500541B2 (pt)
KR (1) KR101001859B1 (pt)
CN (1) CN100463694C (pt)
AU (1) AU2002355966B2 (pt)
BR (1) BR0212093A (pt)
CA (1) CA2457414C (pt)
HK (1) HK1072373A1 (pt)
IL (2) IL160512A0 (pt)
MX (1) MXPA04001585A (pt)
WO (1) WO2003016333A2 (pt)
ZA (1) ZA200402190B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
AU2004308952A1 (en) * 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
WO2007011827A2 (en) * 2005-07-15 2007-01-25 University Of Maryland Biotechnology Institute G1 cytostatic agents enhancing antiviral activity of viral-envelope targeting drugs and antibodies
EP1754715A1 (de) * 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Impfstoff auf Basis virusneutralisierender Antikörper
WO2007024976A2 (en) * 2005-08-23 2007-03-01 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
JP2009517077A (ja) * 2005-11-28 2009-04-30 アーンスティトゥ ド ラ ルシェルシェ プール ル ディべロプマーン キメラｈｉｖ−１糖タンパク質およびそれらの生物学的用途
WO2007084568A2 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
CN101899100B (zh) * 2007-02-02 2013-04-03 同济大学 抗hiv-i的多肽、其编码序列及其用途
CA2719522A1 (en) * 2007-03-26 2008-10-02 University Of Maryland, Baltimore A non-destructive method to quantify and isolate antigen-specific b cells and uses thereof
JP5683948B2 (ja) * 2007-05-14 2015-03-11 バンクーバー バイオテク リミテッド 糖を含有する全ての（ｐａｎ）癌のマーカー
WO2011109511A2 (en) * 2010-03-02 2011-09-09 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011248279A1 (en) 2010-05-03 2012-11-01 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP6704000B2 (ja) * 2015-04-24 2020-06-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｒｏｒ１−ｒｏｒ２結合のモジュレーター
EP3475446A1 (en) * 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018207023A2 (en) * 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405914D0 (en) 1994-03-24 1994-05-11 Discovision Ass Video decompression
ATE135747T1 (de) 1986-08-21 1996-04-15 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
IL83687A (en) 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
EP0550516A1 (en) 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
JP2767078B2 (ja) 1990-10-17 1998-06-18 アメリカ合衆国 Ｈｉｖ―１の分子クローンとその使用法
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
DE69328726D1 (de) 1992-02-10 2000-06-29 Univ Durham Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
WO1994015638A1 (en) 1992-12-31 1994-07-21 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
US5925741A (en) 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
ATE207760T1 (de) 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
EP0705334A1 (en) 1993-06-14 1996-04-10 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5695977A (en) 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
AU7127798A (en) 1997-04-18 1998-11-13 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
DK1137786T3 (da) * 1999-10-08 2007-08-06 Univ Maryland Biotech Inst Viruscoatprotein/receptorkimærer og fremgangsmåder til brug heraf

Also Published As

Publication number Publication date
EP1425036A4 (en) 2007-01-10
CN100463694C (zh) 2009-02-25
MXPA04001585A (es) 2005-03-07
HK1072373A1 (en) 2005-08-26
IL160512A0 (en) 2004-07-25
CA2457414C (en) 2012-08-07
KR20040049841A (ko) 2004-06-12
WO2003016333A3 (en) 2003-07-31
KR101001859B1 (ko) 2010-12-17
US20020155121A1 (en) 2002-10-24
US7399473B2 (en) 2008-07-15
CA2457414A1 (en) 2003-02-27
WO2003016333A2 (en) 2003-02-27
CN1561229A (zh) 2005-01-05
ZA200402190B (en) 2005-07-27
JP4500541B2 (ja) 2010-07-14
US6908612B2 (en) 2005-06-21
US20050221445A1 (en) 2005-10-06
AU2002355966B2 (en) 2007-01-18
IL204302A (en) 2011-04-28
JP2005503147A (ja) 2005-02-03
EP1425036A2 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
BR0212093A (pt) Quimeras de proteìna de envelope viral/receptor e métods de utilização
CA2435972A1 (en) Matrix attachment regions and methods for use thereof
CA2096159A1 (en) Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
ATE290880T1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
PE64396A1 (es) Proteina accesoria del receptor de la interleucina 1
CY1113731T1 (el) Μεθοδοι για δημιουργια παρασκευασματων κομιστων ανασυνδυασμενου aav υψηλου τιτλου απαλλαγμενων απο βοηθητικο ιο
AU2002257420A1 (en) A system for inducible expression in eukaryotic cells
BR9813740A (pt) Teriparatìdeo cristalino
HUP0004896A1 (hu) HIV-1 Tat és/vagy Nef fehérjéket tartalmazó fúziós fehérjék
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
BRPI0211191B8 (pt) ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios
BR9810478A (pt) Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
DE50000767D1 (de) Mit nanopartikeln modifizierte bindemittel für überzugsmittel und deren verwendung
ATE443158T1 (de) Vektorvermittelte organellentransfektion
CY1106691T1 (el) Πρωτεϊνη του καψιδιου ιου/χιμαιρες υποδοχεα και μεθοδοι χρησης
ATE207963T1 (de) Retrovirale vektoren, verfahren zu ihrer herstellung und ihre verwendung zur genübertragung in cd4-positive zellen
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
ATE343592T1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
BR112023019385A2 (pt) Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso
ES2074422T3 (es) Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
IL175332A0 (en) High throughput functional assay for g-protein coupled receptors using a rap-ras chimeric protein
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
US7244814B2 (en) Variant Tat proteins and methods for use thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 09/934,060 DE 21/08/2001, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16, 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE NO PRAZO LEGAL, TENDO EM VISTA QUE O TITULAR DA PRIORIDADE E DIFERENTE DO DEPOSITANTEDA FASE NACIONAL.

B12F Other appeals [chapter 12.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements